 extent of vector-mediated pro-drug activation. Taken in conjunction, these studies will provide not only justification for a treatment modality that we will be able to test in phase I clinical trials, but also a mechanistic insight into the variables affecting cytotoxicity by the viral and pro-drug activation. The field of evolutionary biology has long
extent of vector - mediated pro - drug activation. Taken in conjunction, these report will leave not only justification for a treatment modality that we will be able to quiz in phase I clinical trials, but also a mechanistic penetration into the variables affecting cytotoxicity by the viral and pro - drug activation. The battlefield of evolutionary biology has long
 exhent of vector-mediated pvo-drug activatiou. Taken in cohjunctiov, these studies will provide nit onoy justification for a treatmenn modalitt thet we will be able to test in lmase N rlinical trials, but also d mechanistic hnriyht into the variables affecting cytjtoxiciyy by the viral wnd kro-qrug activation. The field of evolutionzry bionogy has long
extent of vector-mediated pro-drug activation. Taken in studies provide not justification for a be to test in I clinical trials, also a mechanistic insight into the affecting cytotoxicity by the viral and pro-drug activation. The field of evolutionary biology long
 extent of vector-mediated pro-Drug activaTion. TAkeN in CoNjunCtioN, these studies wILl prOvide not only justificatIon foR a TReatMEnT modaLity thaT We WILl bE aBlE to TeST iN phasE I cLinical Trials, but aLso A mEchanistic inSIgHt into the vAriAbles affectiNg cYtotoxIcIty BY the vIraL and pRo-drug ACtivatIon. The fieLd OF evoluTIonary bIOLoGy haS long
 extent of vector-mediated  pro-drugactiv ati on.  T aken  inconjunction, t h esestudies will provide n ot on ly just i fi catio n for a tr e a tme nt  m oda li t ythatwewill be  able to t est  i n phase I cl i ni cal trials , b ut also a me cha nistic  i nsi g ht in tothe v ariabl e s affe cting cyt ot o xicity by thev i ra l an d pro-drug activa t io n . The field of  evolu ti o na r y  bi olo gy has lon g
 extent_of vector-mediated_pro-drug activation. Taken in_conjunction, these_studies_will provide_not_only justification for_a treatment modality_that we will be_able to test_in_phase I clinical trials, but also a mechanistic insight into the variables affecting cytotoxicity_by_the viral_and_pro-drug_activation. The field of evolutionary_biology has long